NCT07492355CompletedPhase 1
TP-3654 Food Effect Study
A Phase 1 Randomized Study in Healthy Adult Participants to Assess the Relative Bioavailability of and Effect of Food on TP-3654 Capsule Formulations
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
This clinical trial will determine the bioavailability and effect of food on TP-3654 in healthy adult participants.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 19 Mar 2026
- Start date
- 4 Mar 2024
- Primary completion date
- 31 May 2024
- Lead sponsor
- Sumitomo Pharma America, Inc.
- NCT number
- NCT07492355
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- From 4 Mar 2024 to the primary completion date, 31 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exposure to other investigational product
Other illness
- History of alcohol and recreational drug use including smoking and/or use of nicotine products.
Other
- Pregnancy
- Clinically significant medical history
Who the study is looking for
- Participant has a BMI ≥ 18.5 and ≤ 32 kg/m2 at screening.
- Participant is generally healthy, as determined by the Investigator based on medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG at screening.
- Participant agrees to avoid the use of concomitant medications (except hormonal contraception or medication provided by the site staff under the direction of the Investigator) from time of screening through the final follow-up visit.
- Participant agrees to abstain from alcohol, recreational drugs (including marijuana), and nicotine from time of screening through the final follow-up visit.
- Participant agrees to use acceptable method of contraception during the duration of the study and up to 6 months after last dose.
- Participant agrees to not donate eggs or sperm during the study and up to 6 months after last dose.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Frontage Clinical Coordinator of this site? Confirm its status | Secaucus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.